The Alliance for Clinical Trials in Oncology will host a public webinar on Monday, September 29, at 12 pm CT showcasing key findings of Alliance research presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. The clinical trial results discussed at the virtual meeting will include some of the latest guidance for people living with colorectal, squamous cell, and renal cell cancers
August 5, 2025
Alliance A012303: ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade
Adrienne Waks, MD, of the Dana-Farber Cancer Institute, leads this phase III trial that compares six months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treat
June 1, 2025
The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch re
